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Abstract
Background: The on-field diagnosis of sports-related concussion (SRC) is complicated by the lack of an accurate and
objective marker of brain injury.
Purpose: To compare subject-specific changes in the astroglial protein, S100B, before and after SRC among collegiate and
semi-professional contact sport athletes, and compare these changes to differences in S100B before and after non-contact
exertion.
Study Design: Longitudinal cohort study.
Methods: From 2009–2011, we performed a prospective study of athletes from Munich, Germany, and Rochester, New York,
USA. Serum S100B was measured in all SRC athletes at pre-season baseline, within 3 hours of injury, and at days 2, 3 and 7
post-SRC. Among a subset of athletes, S100B was measured after non-contact exertion but before injury. All samples were
collected identically and analyzed using an automated electrochemiluminescent assay to quantify serum S100B levels.
Results: Forty-six athletes (30 Munich, 16 Rochester) underwent baseline testing. Thirty underwent additional post-exertion
S100B testing. Twenty-two athletes (16 Rochester, 6 Munich) sustained a SRC, and 17 had S100B testing within 3 hours post-
injury. The mean 3-hour post-SRC S100B was significantly higher than pre-season baseline (0.09960.008 mg/L vs.
0.05860.006 mg/L, p = 0.0002). Mean post-exertion S100B was not significantly different than the preseason baseline. S100B
levels at post-injury days 2, 3 and 7 were significantly lower than the 3-hour level, and not different than baseline. Both the
absolute change and proportional increase in S100B 3-hour post-injury were accurate discriminators of SRC from non-
contact exertion without SRC (AUC 0.772 and 0.904, respectively). A 3-hour post-concussion S100B .0.122 mg/L and a
proportional S100B increase of .45.9% over baseline were both 96.7% specific for SRC.
Conclusions: Relative and absolute increases in serum S100B can accurately distinguish SRC from sports-related exertion,
and may be a useful adjunct to the diagnosis of SRC.
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Introduction
Sports-related concussions (SRC) are common in both the
United States and Germany. In the US, the Centers for Disease
Control and Prevention estimates that there are 1.6–3.8 million
SRC per year [1], with the highest concussion rates found among
contact sports such as ice hockey, football, soccer, and basketball
[2].While there are no similar cumulative figures for Germany, a
recent epidemiological survey found the overall incidence of
traumatic brain injuries (TBI) to be 330/100,000 inhabitants and
that 6.3% of these were due to sports [3,4]. With the current
German population at just over 81.5 million, that translates into
over 268,000 sports TBIs per year.
After a concussion, most athletes recover within 7–10 days [5],
but up to 10% have post-concussion symptoms such as headache
and dizziness lasting longer than 7 days [6,7]. In addition, multiple
concussions are thought to be linked to the early onset of
neurodegeneration, known as chronic traumatic encephalopathy
[8]. Existing concussion management guidelines are designed to
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mitigate these risks and involve primarily rest [5]. However, the
effect of these guidelines on reducing long-term disability depends
entirely on recognizing that a concussion has occurred in the first
place. While sideline tools such as SAC [9], SCAT 2 [5], and
SCAT 3 [10] are designed to assist coaches and certified athletic
trainers in identifying the mental status changes (loss of
consciousness, amnesia, confusion) that are the hallmark of this
injury, unrecognized or unreported concussions are still quite
common, occurring in over half of injured high school football
players queried via a confidential survey [11]. An objective
parameter that can be easily and rapidly measured on-site could
optimize the identification and clinical management of concussed
athletes.
Serum S100B has emerged as a potential candidate in this
regard. S100B is a 21 kDa dimeric protein expressed primarily by
brain astrocytes and belongs to a multigenic family of calcium-
binding proteins [12–14]. Its primary clinical role in concussion
management has been to help identify the approximately 5% of
concussion patients that have intracranial hemorrhage on head
CT scan. Although S100B’s specificity for abnormal head CT is
low (40%), its high sensitivity (99%) [15–17] has led to its adoption
as a clinical tool to screen for head injured patient requiring a head
CT scan (pre-head CT screen) in several countries in Europe and
Asia.
Enthusiasm for the use of S100B to aid in the diagnosis of
concussion, however, has been tempered by significant overlap
between levels in healthy individuals and in athletes who have had
a concussion. Using cutoffs derived from comparing these two
groups, only very high S100B levels—rarely seen after concussion–
are considered abnormal, making this test appear clinically useless
in a sports setting. However, small but significant post-concussion
increases can be revealed by comparing S100B values not among
groups, but in individual athletes before injury to that after injury.
This kind of study is expensive and labor-intensive to perform
because one cannot predict which athletes will get injured during a
season; serum must be obtained from several hundred athletes in
order to accrue pre and post-concussion samples in 20–30 athletes.
A second problem for using S100B clinically is the observation
that serum levels rise not only after concussion but also after a
game in which no concussion was observed [18–21]. Explanations
for this observation range from exertion-related release of small
amounts of S100B from melanocytes, chondrocytes and adipo-
cytes [12], to occult or unreported brain injury, or a combination
of the two. In order to separate the effect of these two processes on
S100B, one needs to compare S100B increases in concussed
athletes to that in a group of athletes undergoing exertion but not
body contact in whom the risk of even occult brain injury is very
low.
In an effort to unlock the diagnostic potential of S100B, we
sought to compare subject-specific changes in S100B before and
after concussion among collegiate and semi-professional athletes.
Our secondary aim was to compare these changes to differences in
S100B before and after non-contact exertion. By using an intra-
subject, before-and-after study design, we minimized the effect
that individual-level variation in baseline S100B levels has on
obscuring group-level post-concussion increases. In addition, by
examining S100B changes in a reference group not undergoing
sports-related contact, we sought to minimize the probability that
S100B elevations in the comparison group are due to occult brain
injury.
Methods
We performed a longitudinal cohort study of contact sport
athletes in Munich and Rochester between 2009 and 2011.
Ethics Statement
The study was approved by the ethics committees of the Ludwig
Maximilians University in Munich, Germany and at the Rochester
Institute of Technology and University of Rochester in Rochester,
NY, USA. Voluntary participation was solicited through commu-
nication with athletic directors, coaches, and athletes. All
participating athletes completed written informed consent forms
before inclusion in the study, which described the purpose,
objective, and details of the testing and research participation.
Inclusion and Exclusion Criteria
Athletes were eligible for inclusion if they were $18 years of age
and active participants in contact sport teams affiliated with the
Ludwig Maximilians University in Munich, Germany, or with the
University of Rochester or Rochester Institute of Technology in
Rochester, New York.
The University of Rochester participates in several National
Collegiate Athletic Association (NCAA) Division III sports
including the following contact sports: football, soccer, and
basketball. In addition, the University of Rochester provides
orthopedic and trauma care to hockey players at Rochester
Institute of Technology (men participate in NCAA Division I and
women, at the time of the study, in Division III). Athletes from
these teams were eligible to participate. Although German
universities don’t participate in US-style collegiate athletic
organizations, the Ludwig Maximilians University provides
orthopedic and trauma care to the Straubing Tigers Ice Hockey
Club which is a semi-professional ice hockey team that currently
plays in the Deutsche Eishockey Liga (German National Ice Hockey
League). Athletes from this team were eligible to participate in the
current study.
Athletes who sustained a moderate or severe TBI (determined
by a hospital GCS of 3–12) were excluded from the study. Athletes
who sustained a concussion within two weeks of baseline (ie:
during the off-season or during a non-sport activity) were also
excluded. History of prior head injury was determined by self-
report using a previously validated survey tool[22].
Serum Sampling
Among Rochester athletes, baseline samples were collected on
all participating athletes but analyzed for S100B only in those who
subsequently developed concussion. Samples were collected within
3 hours of SRC and at days 2, 3 and 7 post-concussion. Among
Munich athletes, baseline samples were collected and analyzed for
S100B in all participants, then again after a period of exertion (but
before injury), and finally on the subset who suffered a concussion,
also within 3 hours of injury (Table 1). Exertion consisted of non-
contact ice-hockey skating drills. Post exertion testing was limited
to Munich athletes principally for reasons of convenience. The
Straubing Tigers had the largest number of participating athletes
of any single participating team, as well and a regular practice
schedule made in advance. These factors facilitated post-exertion
serum sample with a minimum of study personnel. Because
members of Straubing Tigers were frequently on the road, post-
concussion serum was not obtained from Munich athletes beyond
the 3-hour time point.The study group thus consisted of athletes
with S100B samples obtained before and after concussion, and the
comparison group consisted of athletes with S100B samples
obtained before and after non-contact exertion.
Serum S-100B after Sports-Related Concussion
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Athletes were considered concussed if they had an injury
witnessed by an on-field coach or certified athletic trainer meeting
the definition of concussion defined by the Sport Concussion
Assessment Tool 2 (SCAT2) [5]. This definition consists of an
injury resulting in any one or more of the following: symptoms
(such as headache), physical signs (such as unsteadiness), impaired
brain function (such as confusion), or abnormal behavior.
Methods for obtaining and handling serum were identical at
both sites. Four milliliters of venous blood was drawn into sterile
Vacuatiner serum separator tubes and immediately placed on 0uC
ice. Within 60 minutes, the blood was centrifuged (3000 rpm, 10
minutes), and the serum separated and stored at 280uC until
sample analysis.
Serum S100B Measurement
Serum S100B concentrations were determined by electroche-
moluminometric immunoassay (ELECSYSH S100, ROCHE
Diagnostics, Mannheim, Germany) with a detection limit of
0.005–39 mg/L, according to the manufacturer’s instructions..
Briefly, two monoclonal antibodies directed against the beta-chain
of the S100 dimer were inclubated with 20 ml of sample for 9
minutes. Streptavidin-coated microparticles were added, and the
mixture was incubated for an additional 9 minutes in order to
form a solidified immunocomplex. The reaction mixture was
transferred to a measurement cell where the beads were
magnetically captured on an elctrode surface, and unbound
components were removed by washing. A defined voltage was
applied to the electrode to initiate the electrochemiluminescent
reaction and the resultant light emission was measured using a
photomultiplier. Serum S100B concentrations were reported as
mg/L of serum and reported as mean values 6 SD. Reference
range of S100B is 0.02 to 0.15 mg/L [23].
Analysis
Serum S100B concentrations before and after SRC, as well as
before and after non-contact exertion, were compared using
paired t-tests. Changes in S100B concentrations among all
concussed athletes were compared using paired and unpaired t-
tests. Receiver operating characteristic (ROC) analyses were
performed to evaluate S100B’s classification accuracy for SRC
[24]. In these analyses, S100B levels within 3 hours of concussion
were compared to S100B levels after non-contact exertion. We
examined the ROC of the post-SRC or post-exertion S100B value
as well as the proportional change in post-concussion/exertion
S100B relative to preseason (baseline). The proportional change
was defined as [(post-exertion or 3-hour post-SRC S100B –
baseline S100B)/baseline S100B]. Analyses were performed using
SASHSoftware Version 9.3 (SAS Institute Inc., Cary, NC, USA)
and GraphPad Prism Version 5.02 for Windows (GraphPad
Software, La Jolla California USA). A p-value of #0.05 was
considered statistically significant.
This study was designed to to detect clinically-relevant increases
in S100B. Because the sample size was fixed by the number of
concussed subjects (46), we report here the power this sample size
had to detect clinically relevant S100B increases. Cliniclaly-
relevant increases were defined based on prior studies reporting
baseline S100B levels in athletes ranging from 0.11–0.22 ug/L
(SD range 0.04–0.04 ug/L) that increased by 36–64% after
exertion[20,25]. Thus, assuming a Type I error of 0.05, mean
baseline S100B level of 0.11 ug/L, and SD in mean baseline
S100B of 0.05 ug/L, 46 sujbects provides 96% power to detect an
increase of 25% or greater in mean baseline S100B levels.
Results
Thirty Munich athletes agreed to participate, providing baseline
and post-exertion serum samples. All of these samples were
analyzed for S100B. Six of these athletes suffered a SRC during
the study period (Table 1). A total of 306 Rochester athletes
agreed to participate, providing baseline (but not post-exertion)
serum samples. Sixteen of these athletes suffered a SRC during the
study period. Only the serum samples from the 16 concussed
Rochester athletes were analyzed for S100B at baseline and after
SRC. The initial, within-3-hour serum sample was not obtained in
five of these 16 athletes because the SRC occurred during a game
outside the Rochester area; however, subsequent samples were
obtained at the later time points.
Forty-six athletes (30 from Munich and 16 from Rochester) had
baseline samples, as well as post-exertion and/or post-SRC
samples, analyzed for S100B. The mean age of all athletes was
25.4 years and 89% were male (Table 2). The mean age of
Munich athletes was significantly greater than the mean age of
Rochester athletes (28.460.82 years vs. 19.860.34 years, p,
0.001). The mean baseline S100B concentration among Munich
athletes was not significantly different than the mean baseline
concentration among Rochester athletes (0.07060.03 mg/L vs.
0.06860.04 mg/L, p = 0.85).
Among the 30 Munich athletes who underwent post-exertion
S100B testing, there was no difference in mean post-exertion
S100B level compared to baseline (0.07160.03 mg/L vs.
0.07060.03 mg/L, p = 0.87) (Figure 1). Proportional post-exer-
tion changes in S100B ranged from 235 to +50%. The mean
proportional post-exertion S100B change was +2.7%.
During the study period, 22 athletes (17 male and 5 female; 16
from Rochester and 6 from Munich) suffered a SRC, of which
serum samples were collected within 3-hours of injury from 17
individuals (11 from Rochester and 6 from Munich). None of these
concussions were accompanied by other extracranial fractures or
lacerations. Among these 17 athletes, the mean S100B level within
3 hours of injury was significantly higher than baseline
(0.09960.008 mg/L vs. 0.05860.006 mg/L, paired t-test p,
0.0001; Figure 1). Proportional post-SRC changes in S100B
ranged from 214 to +180%. The mean post-SRC S100B change
was +81.2%. Longitudinal S100B levels measured post-injury days
2, 3 and 7 were not significantly different than baseline, although
they were all significantly lower than the 3-hour post injury level
(Figure 2).
The ROC using the absolute value 3-hour post-injury/
exertional S100B value revealed an AUC of 0.772 (95% CI:
0.64, 0.91). However the AUC using the proportional increase in
post-injury/exertional S100B level over baseline was higher





30 Pre-season (resting) S100B 16
30 Post-exertion S100B 0
6 Concussion 16
6 3-hours Post-Concussion S100B 11
0 2 days Post-Concussion S100B 16
0 3 days Post-Concussion S100B 15
0 7 days Post-Concussion S100B 16
doi:10.1371/journal.pone.0084977.t001
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(0.904, 95% CI: 0.80, 1.0; Figure 3). Cutoff values that maximize
sensitivity and specificity for SRC diagnosis are shown in Table 3.
A 3-hour post-concussion S100B level of .0.122 mg/L and a
proportional S100B increase of .45.9% over baseline were both
96.7% specific for concussion.
Table 2. Subject characteristics.
Characteristic Munich Athletes (n = 30) Rochester Athletes (n = 16) Combined Cohort (n = 46)
Age, Mean Years (SD) 28.4 (4.5) 19.8 (1.4) 25.4 (5.5)
Male, N (%) 30 (100) 11(68.8) 41 (89.1)
Race
Caucasian, N (%) 30 (100) 14 (87.5) 44 (95.7)
African American/European, N (%) 0 2 (12.5) 2 (4.3)
Sport
Ice Hockey, N (%) 30 (100) 4 (25) 34 (73.9)
Soccer, N (%) 0 3 (18.8) 3 (6.5)
Football, N (%) 0 8 (50) 8 (17.4)
Basketball, N (%) 0 1 (6.2) 1 (2.2)
Baseline S100B, mean mg/L (SD)* 0.070 (.03) 0.068 (.04) 0.070 (.03)
*T-test to assess difference between Munich and Rochester cohorts at baseline, p = 0.85.
doi:10.1371/journal.pone.0084977.t002
Figure 1. S100B Changes after non-contact exertion and sports-related concussion. A: Absolute (Left) and proportional (right) changes in
S100B levels after non-contact exertion among individal athletes. The proportional change is defined as (post-exertion or 3-hour post-SRC S100B –
baseline S100B)/baseline S100B (range: 235% to +50%; mean proportional change = +2.7%). The mean post-exertional S100B concentration
(0.07160.03 mg/L) was not significantly different from mean baseline (0.07060.03 mg/L, *p = 0.87, Middle). B: Absolute (Left) and proportional (right)
changes in S100B levels within 3 hours of SRC among individual athletes. The mean post-SRC S100B concentration within 3 hours of concussion
(0.09960.008 mg/L) was significantly higher than that at baseline (0.05860.006 mg/L, **p = 0.0002, Middle). Proportional change (right) ranged from
214% to +180%; mean proportional change +81.2%). Munich athletes are designated in red, Rochester athletes in black.
doi:10.1371/journal.pone.0084977.g001
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Discussion
The current approach to diagnosing SRC is complicated by the
subjective nature of the current sideline assessment tools as well as
by symptom minimization among athletes motivated to remain in
the game [11]. The lack of an objective and accurate diagnostic
aid hinders efforts to minimize both the short and long-term
consequences of SRC.
In the current study, we have demonstrated that elevated S100B
measured within 3 hours of injury is an accurate discriminator of
SRC from sport-related exertion. Classification accuracy is greatly
enhanced if the post-injury value is compared to a pre-season
baseline. This will come as little surprise to those accustomed to
comparing an injured athlete’s post-concussion cognitive test
scores to their pre-season scores. Unlike tests of cognition,
however, measurements of serum S100B are less likely to be
affected by stress, sleep deprivation, and pain. Moreover, baseline
levels can’t be manipulated by athletes trying to minimize the
effects of potential future concussions. On the other hand, unlike
cognitive performance, which can remain abnormal for weeks
Figure 2. Longitudinal changes in S100B before and after sports-related concussion. A: Mean changes in S100B levels among all
concussed athletes at baseline and at four time points after injury. The number of athletes included in determining the mean at each time point is
indicated below each box plot. The mean S100B concentration within 3 hours of SRC (0.09960.032 mg/L) was significantly higher than that at
baseline (0.05860.025 mg/L, *p,0.0001) using a paired t-test. The 3 hour S100B level was also higher than that at 2 days (0.05960.03 mg/L,
++p = 0.0004), 3 days (0.05260.02 mg/L, +p,0.0001), and 7 days (0.05960.03 mg/L, **p = 0.001) post-SRC using unpaired t-tests. B: Longitudinal
changes in S100B levels among concussed athletes who had baseline and all four post-SRC S100B measurements. All 11 of these athletes were from
the Unviersity of Rochester. The mean S100B level within 3 hours of SRC (0.09960.032 mg/L) was significantly higher than that at baseline
(0.05860.025 mg/L, *p,0.0001), and higher than that at 2 days (0.05960.027 mg/L, ++p = 0.0047), 3 days (0.04860.008 mg/L, +p = 0.0002), and 7 days
(0.05660.027 mg/L, **p = 0.0058) post-SRC using paired t-tests.
doi:10.1371/journal.pone.0084977.g002
Figure 3. Diagnostic accuracy of S100B for sports-related concussion. A: The ROC using the 3-hour post-SRC value or the post-exertion
S100B value revealed an AUC of 0.772 (95% CI: 0.64, 0.91). B: The AUC using the proportional increase in post-SRC/exertional S100B level over baseline
was 0.904 (95% CI: 0.80, 1.0).
doi:10.1371/journal.pone.0084977.g003
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after concussion, serum S100B levels are cleared rapidly [26]; in
our study S100B levels were back to baseline by day 2 after SRC.
Thus, while the initial 3 hour level may be a useful adjunct to the
diagnosis of SRC, subsequent S100B levels can’t be used as a
diagnostic aid, and will not be helpful in determining when an
athlete is recovered and ready to return to contact sports.
Based on our preliminary findings, an S100B level of .
0.122 mg/L or a proportional S100B increase of .45.9% over
baseline measured within 3 hours of injury is quite specific for
SRC, while a level ,0.0605 mg/L or a proportional decrease of .
3.5% essentially rules it out. Six concussed athletes had serum
drawn within 15 minutes of injury (5 of 6 were elevated) suggesting
that sampling could be done on the sideline, relatively soon after
injury. The prompt measurement of S100B is ideal, given the
relatively short biological half-life of S100B. Pending confirmation
in larger studies, these results suggest that S100B could be used to
aid in the sideline diagnosis of SRC.
However, several practical issues remain. Although used
clinically in Germany, S100B testing has not been approved by
the FDA for use in the US. In addition, there is currently no
portable, point of care assay for S100B measurement, making
sideline testing problematic. The Roche ElecsysH analyzer used in
the current study is the size of a large desktop printer and requires
a centrifuged venous blood sample. Point of care test devices that
require a finger stick sample of blood are, however, currently
under development [27]. The rollout of these devices would allow
athletic trainers to collect baseline as well as post injury S100B
levels in a training room or athletic field. Baseline finger stick
S100B testing could become integrated into the required pre-
participation physical exam that is part of collegiate and secondary
sports participation in both the US and Germany. This idea may
not be so implausible given the 2010 NCAA regulations in the US
requiring pre-participation blood testing for the sickle cell
trait[28]. The effort required to overcome these obstacles would
be more than offset by the potential benefits of accurately
diagnosing and managing an injury to the brain affecting millions
of athletes around the world.
While our study has many strengths, including a before-and-
after design and a comparison group with a very low risk of occult
brain injury, there are several limitations. The primary results
involved combining data from two seemingly distinct cohorts; one
from Munich and one from Rochester. Although athletes in both
cohorts consisted of young adults playing their sport at a highly
competitive level, the cohorts differed with respect to age, gender,
and sport. They also differed with respect to concussion
prevalance; 20% for the Munich athletes and ,1% for the
Rochester athletes. This difference may be due in part to the
increased concussion risk associated with semi-professional ice
hockey but more likely reflects differences in play time. Munich
athletes played 8 months a year while the collegiate athletes in
Rochester played for only 2–3 months. Because each player served
as their own control, these differences were unlikley to bias the
main results. Moreover, the mean baseline S100B levels are nearly
identical in the two cohorts, as were the patterns of post-injury
S100B change (Table 2 and Figure 1). These observations
underscore the legitimacy of analyzing the groups together.
Finally, all of the SRCs in our study were isolated injuries to the
head, without the potentially confounding effects of extracranial
injuries on S100B elevations. Although others have demonstrated
that the contribution of extracranial S100B to overall serum levels
is negligible [29], our results should be applied with caution to
SRCs accompanied by significant extracrainal injuries such as
fractures.
In summary, current sideline diagnosis of SRC relies on athlete
self-report or trainer/coach recognition using SAC, SCAT 2, or
SCAT 3. Despite this, unrecognized or unreported concussions are
still quite common. Our results suggest that serum S100B
measured within 3 hours of a sports-related injury can accurately
distinguish SRC from sports-related exertion. The accuracy of this
prediction is enhanced if the post-injury level is compared to a pre-
season baseline level, much in the same way that cognitive test
scores are currently interpreted. Serum S100B .0.122 mg/L or a
proportional S100B increase of .45.9% over baseline are highly
specific (96.7%) for SRC. These results suggest that serum S100B
may be a useful adjunct to the diagnosis of SRC.
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